相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent Multimodality Imaging Through 3 Years
Yoshinobu Onuma et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial
Azfar Zaman et al.
LANCET (2019)
Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus 5 years follow-up from the COMPARE II trial
Valeria Paradies et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
How does the failure of Absorb apply to the other bioresorbable scaffolds? An expert review of first-in-man and pivotal trials
Yuki Katagiri et al.
EUROINTERVENTION (2019)
Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels A Prespecified Analysis of the Randomized BIO-RESORT Trial
Rosaly A. Buiten et al.
JAMA CARDIOLOGY (2019)
Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents
Rosaly A. Buiten et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2019)
Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up A Systematic Meta-analysis and Individual Patient Data Pooled Study
Gregg W. Stone et al.
JAMA CARDIOLOGY (2019)
Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent Multicenter, Noninferiority Trial (ReCre8)
Rik Rozemeijer et al.
CIRCULATION (2019)
Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial
Chun Chin Chang et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2019)
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents Final Report of the DUTCH PEERS (TWENTE II) Trial
Paolo Zocca et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial
Carlo Zivelonghi et al.
JOURNAL OF INTERVENTIONAL CARDIOLOGY (2018)
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial
Robbert J. de Winter et al.
LANCET (2018)
Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: a single-centre experience with report of specific angiographic indications
H. Lu et al.
NETHERLANDS HEART JOURNAL (2018)
First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
Clemens von Birgelen et al.
EUROINTERVENTION (2018)
A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial
Valeria Paradies et al.
EUROINTERVENTION (2018)
Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)
Bernard Chevalier et al.
EUROINTERVENTION (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx et al.
LANCET (2018)
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial
Clemens von Birgelen et al.
LANCET (2018)
1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent Primary Results of the COMBO Collaboration
Robbert J. de Winter et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis
Pier Woudstra et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2018)
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI
Ruben Y. G. Tijssen et al.
EUROINTERVENTION (2018)
Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions The PRISON IV Trial
Koen Teeuwen et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent)
Georgios J. Vlachojannis et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents
Patrick W. Serruys et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
Joanna J. Wykrzykowska et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients A Secondary Analysis of a Randomized Clinical Trial
Clemens von Birgelen et al.
JAMA CARDIOLOGY (2017)
In situ heart valve tissue engineering using a bioresorbable elastomeric implant - From material design to 12 months follow-up in sheep
Jolanda Kluin et al.
BIOMATERIALS (2017)
First Generation Versus Second Generation Drug-Eluting Stents for the Treatment of Bifurcations: 5-Year Follow-Up of the LEADERS All-Comers Randomized Trial
Maik J. Grundeken et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2016)
Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial
Liefke C. van der Heijden et al.
CLINICAL RESEARCH IN CARDIOLOGY (2016)
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial
Manel Sabate et al.
EUROPEAN HEART JOURNAL (2016)
1-Year Results of the REMEDEE Registry Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry
Pier Woudstra et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis 5-Year Follow-Up
Patrick W. Serruys et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial
Clemens von Birgelen et al.
LANCET (2016)
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Patrick W. Serruys et al.
LANCET (2016)
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial
Manel Sabate et al.
LANCET (2016)
Resultados de los stents Resolute Integrity y Promus Element en el infarto de miocardio: análisis del ensayo aleatorizado DUTCH PEERS (TWENTE II )
K. Gert van Houwelingen et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2016)
Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial
Yoshinobu Onuma et al.
EUROINTERVENTION (2016)
STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial
Robert-Jan M. van Geuns et al.
EUROINTERVENTION (2016)
Evaluation of myocardial blood flow and coronary flow reserve after implantation of a bioresorbable vascular scaffold versus metal drug-eluting stent: an interim one-month analysis of the VANISH trial
Wijnand J. Stuijfzand et al.
EUROINTERVENTION (2016)
DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial
Javaid Iqbal et al.
EUROINTERVENTION (2016)
A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan
Takeshi Kimura et al.
EUROPEAN HEART JOURNAL (2015)
Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice)
Pieter C. Smits et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2015)
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease ABSORB China Trial
Runlin Gao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
Patrick W. Serruys et al.
LANCET (2015)
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Stephen G. Ellis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial
Sjoerd H. Hofma et al.
EUROINTERVENTION (2015)
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Koen Teeuwen et al.
EUROINTERVENTION (2015)
Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction
Yao-Jun Zhang et al.
HEART (2015)
Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction
Inge Wijnbergen et al.
CORONARY ARTERY DISEASE (2014)
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial
Clemens von Birgelen et al.
LANCET (2014)
Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction
M. A. Velders et al.
NETHERLANDS HEART JOURNAL (2014)
Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial
Roberto Diletti et al.
HEART (2013)
Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease
Yoshinobu Onuma et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Noninferiority Trial
Patrick W. Serruys et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial
Pieter Cornelis Smits et al.
LANCET (2013)
Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
Matthijs A. Velders et al.
PLOS ONE (2013)
Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial
Yoshinobu Onuma et al.
EUROINTERVENTION (2013)
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Ben J. L. Van den Branden et al.
EUROINTERVENTION (2013)
Comparison of Drug-Eluting and Bare-Metal Stents for Primary Percutaneous Coronary Intervention With or Without Abciximab in ST-Segment Elevation Myocardial Infarction DEBATER: The Eindhoven Reperfusion Study
Inge Wijnbergen et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2012)
Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study Self-Expanding Stents in ST-Segment Elevation Myocardial Infarction
Robert-Jan van Geuns et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2012)
Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction 1-Year Results of the Randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) Trial
Sjoerd H. Hofma et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients The TWENTE Trial
Clemens von Birgelen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial
Helen Boden et al.
EUROINTERVENTION (2012)
Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)
Ben J. L. Van den Branden et al.
EUROINTERVENTION (2012)
Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents
Hanim Sen et al.
EUROINTERVENTION (2012)
5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction A Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial
Maarten A. Vink et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study-High Risk of Restenosis) A Multicenter, Randomized Trial Comparing Genous Endothelial Progenitor Cell Capturing Stents With Drug-Eluting Stents
Margo Klomp et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Efficacy of Everolimus Eluting Stent Implantation in Patients With Calcified Coronary Culprit Lesions: Two-Year Angiographic and Three-Year Clinical Results From the SPIRIT II Study
Yoshinobu Onuma et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2010)
Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study
Marcel A. M. Beijk et al.
EUROPEAN HEART JOURNAL (2010)
Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials
Yoshinobu Onuma et al.
EUROPEAN HEART JOURNAL (2010)
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
Elvin Kedhi et al.
LANCET (2010)
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
Patrick W. Serruys et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study
Patrick W. Serruys et al.
EUROINTERVENTION (2010)
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
Patrick W. Serruys et al.
LANCET (2009)
Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention
Gerrit J. Laarman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients
H Suryapranata et al.
HEART (2005)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
M Morice et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
